CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy
Joel W. Neal(Stanford Medicine), Thomas Newsom-Davis(Chelsea and Westminster Hospital), Daniel C. Christoph(Evangelisches Krankenhaus Königin Elisabeth Herzberge), Alessandra Bearz(Centro di Riferimento Oncologico), Vilma Graupner(Roche (Switzerland)), Ramón Palmero(Institut Català d'Oncologia), Yasushi Goto(Tennessee Oncology), Xavier Quantin(Inserm), Sun Min Lim(Yonsei University), Elaine W. Chun, Ya‐Chen Lin, Giannis Mountzios(Henry Dunant Hospital), Sang‐We Kim(Ulsan College), Mahrukh Huseni(Gene Therapy Laboratory), Vladan Antic(Roche (Switzerland)), Tirupathi Rao Edubilli(Roche (United Kingdom)), Nick Pavlakis(The University of Sydney), Elena Fountzilas(St. Luke's Hospital), Dominic Curran(Exelixis (United States)), Piet Vervaet(Exelixis (United States)), Marcus Ballinger, Anastasia Mochalova
Cited by 57
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k